Vaxart (VXRT) Price & Analysis

Compare

4,358 Followers

VXRT Stock Chart & Stats

Day’s Range― - ―

52-Week Range$0.26 - $1.07

Previous CloseN/A

Volume1.40M

Average Volume (3M)837.47K

Market Cap

$81.64M

Enterprise Value$95.97M

Total Cash (Recent Filing)$26.27M

Total Debt (Recent Filing)$16.11M

Price to Earnings (P/E)―

Beta1.89

Next Earnings

Nov 13, 2025

EPS Estimate

-0.07

Last Dividend Ex-Date

Nov 09, 2012

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.07

Shares Outstanding228,919,070

10 Day Avg. Volume510,018

30 Day Avg. Volume837,472

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap1.18

Enterprise Value/Revenue1.19

Enterprise Value/Gross Profit1.19

Enterprise Value/Ebitda-2.17

Forecast

1Y Price Target

$4.17

Price Target Upside1027.03% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering3

Bulls Say, Bears Say

Bulls Say

Clinical TrialsThe Phase II COVID-19 vaccine trial is progressing rapidly, with the sentinel cohort enrollment ahead of schedule, indicating strong advancement in the study.

Growth PotentialVaxart's efforts to refine its norovirus program address a significant unmet need in a market with no approved vaccines, showcasing potential for growth and innovation.

Regulatory MilestonesVXRT's norovirus oral vaccine unique competitive position to further benefit from upcoming regulatory milestones.

Vaccine DevelopmentVaxart advances with $453M BARDA-backed COVID-19 vaccine, poised to lead in mucosal immunity.

Bears Say

Investor PerceptionInvestor perception of the norovirus opportunity has considerable room for improvement given the significant disease burden and the lack of approved or late-stage programs.

Vaxart News

Vaxart stockholders unite to oppose latest reverse stock split

Richard John Burgess, Daniel Houle, Michael Patrick Kelley, Marc Eustace Pereira, Patrice Raffy, Benjamin Sauv, Matthew Wallace, MD...

8d ago

VXRT

Vaxart reports Q2 EPS (7c), consensus (9c)

Reports Q2 revenue $39.73M vs. $6.4B last year. Revenue in the second quarter was primarily from government contracts...

15d ago

VXRT

Vaxart reports Q2 EPS (7c), consensus (9c)

Reports Q2 revenue $39.73M, consensus $2.03M. Revenue in Q2 was primarily from government contracts related to the BARDA...

15d ago

VXRT

Options Volatility and Implied Earnings Moves Today, August 13, 2025

Today, several major companies are expected to report earnings: Cisco Systems (CSCO), Stratasys (SSYS), Vaxart (VXRT), OrganiGram Holdings...

16d ago

OGI

ALLO

Options Volatility and Implied Earnings Moves This Week, August 11 – August 14, 2025

This week, several major companies will be reporting earnings. Among them are Plug Power (PLUG), Cisco Systems (CSCO),...

18d ago

Vaxart issues letter to shareholders related to reverse stock split proposal

Vaxart (VXRT) issued the following letter to its stockholders from its President & Chief Executive Officer, Steven Lo....

21d ago

VXRT

Vaxart Discusses Reverse Stock Split Proposal

Vaxart ( ($VXRT) ) has provided an announcement. On August 20, 2025, Vaxart, Inc. held a virtual fireside...

7d ago

VXRT

Vaxart Schedules Fireside Chat on Stock Split

An update from Vaxart ( ($VXRT) ) is now available. On August 14, 2025, Vaxart announced a virtual...

13d ago

VXRT

Vaxart Reports Q2 2025 Earnings and Vaccine Progress

Vaxart ( ($VXRT) ) has released its Q2 earnings. Here is a breakdown of the information Vaxart presented...

15d ago

VXRT

VXRT Earnings this Week: How Will it Perform?

Vaxart (VXRT) is scheduled to report 2nd quarter earnings on 08/13/2025, after the market closes. Regarding Q2 estimates,...

18d ago

VXRT

Vaxart Stock Approved for OTCQX Best Market

Vaxart ( ($VXRT) ) has provided an update. On July 8, 2025, Vaxart announced that its common stock...

2M ago

VXRT

Vaxart announces trading on OTCQX Best Market

Vaxart (VXRT) announced its common stock has been approved to trade on the OTCQX Best Market. The Company’s...

2M ago

VXRT

OTC Markets Group welcomes Vaxart to OTCQX

OTC Markets Group announced Vaxart (VXRT) has qualified to trade on the OTCQX Best Market. Vaxart, Inc. previously...

2M ago

VXRT

Vaxart Stockholders Reject Reverse Stock Split Proposal

Vaxart ( ($VXRT) ) has issued an announcement. On June 13, 2025, Vaxart held its reconvened 2025 annual...

2M ago

VXRT

VXRT FAQ

What was Vaxart Inc’s price range in the past 12 months?

Vaxart Inc lowest stock price was $0.26 and its highest was $1.07 in the past 12 months.

What is Vaxart Inc’s market cap?

Vaxart Inc’s market cap is $81.64M.

When is Vaxart Inc’s upcoming earnings report date?

Vaxart Inc’s upcoming earnings report date is Nov 13, 2025 which is in 76 days.

How were Vaxart Inc’s earnings last quarter?

Vaxart Inc released its earnings results on Aug 13, 2025. The company reported -$0.07 earnings per share for the quarter, beating the consensus estimate of -$0.087 by $0.017.

Is Vaxart Inc overvalued?

According to Wall Street analysts Vaxart Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Vaxart Inc pay dividends?

Vaxart Inc pays a Notavailable dividend of $12.188 which represents an annual dividend yield of N/A. See more information on Vaxart Inc dividends here

What is Vaxart Inc’s EPS estimate?

Vaxart Inc’s EPS estimate is -0.07.

How many shares outstanding does Vaxart Inc have?

Vaxart Inc has 228,919,070 shares outstanding.

What happened to Vaxart Inc’s price movement after its last earnings report?

Vaxart Inc reported an EPS of -$0.07 in its last earnings report, beating expectations of -$0.087. Following the earnings report the stock price went down -2.703%.

Which hedge fund is a major shareholder of Vaxart Inc?

Currently, no hedge funds are holding shares in VXRT

Vaxart Stock Smart Score

Neutral

Fundamentals

Return on Equity

-100.35%

Trailing 12-Months

Asset Growth

44.25%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Vaxart Inc

Vaxart, Inc. (VXRT) is a biotechnology company focused on developing oral vaccines based on its proprietary Vaxart platform. The company operates primarily in the biopharmaceutical sector, specializing in the design and development of innovative vaccines for various infectious diseases, including influenza and norovirus. Vaxart aims to revolutionize immunization through its unique oral delivery system, which is designed to enhance patient compliance and improve immune responses compared to traditional injectable vaccines.

Vaxart (VXRT) Earnings & Revenues

Historic Earnings Reports

VXRT Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Neutral

The earnings call highlighted strong financial growth and promising vaccine development results, but also addressed significant challenges such as the stop work order on a major trial and issues with stock listing compliance. Despite positive advancements in revenue and vaccine capabilities, the operational and financial uncertainties create a balanced sentiment.View all VXRT earnings summaries

VXRT Stock 12 Month Forecast

Average Price Target

$4.17

▲(1027.03% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","9":"$9","-1":"-$1","1.5":"$1.5","6.5":"$6.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$8.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4.17,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$4.17</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$0.50</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,1.5,4,6.5,9],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.36,0.9476923076923076,1.5353846153846153,2.1230769230769226,2.7107692307692304,3.298461538461538,3.8861538461538454,4.473846153846154,5.061538461538461,5.649230769230769,6.236923076923077,6.8246153846153845,7.412307692307691,{"y":8,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.36,0.6530769230769231,0.9461538461538461,1.2392307692307694,1.5323076923076924,1.8253846153846154,2.1184615384615384,2.4115384615384614,2.7046153846153844,2.9976923076923074,3.2907692307692304,3.5838461538461535,3.876923076923077,{"y":4.17,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.36,0.37076923076923074,0.38153846153846155,0.3923076923076923,0.40307692307692305,0.41384615384615386,0.4246153846153846,0.43538461538461537,0.4461538461538461,0.45692307692307693,0.4676923076923077,0.4784615384615385,0.48923076923076925,{"y":0.5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":0.69,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.66,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.82,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.77,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.59,"date":1733011200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.66,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.68,"date":1738368000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.51,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.37,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.43,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.45,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.46,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.36,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >